Molecular Insight Pharmaceuticals, Inc. to Host Conference Call on May 15.- Dr. R. Edward Coleman Edward Coleman may refer to:
The School of Medicine has a unique curriculum among American medical schools. to Join Management for Clinical Update - CAMBRIDGE, Mass. -- Molecular Insight Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : MIPI MIPI Mobile Industry Processor Interface MIPI Music Industry Privacy Investigations ) announced today that it will release its first quarter 2007 financial results before the opening of the stock market and hold a conference call on Tuesday, May 15, 2007 at 10:00 AM EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT . During the call, senior management of Molecular Insight will review the company's financial results and provide an update on its clinical development programs. Dr. R. Edward Coleman, the Principal Investigator Noun 1. principal investigator - the scientist in charge of an experiment or research project PI scientist - a person with advanced knowledge of one or more sciences for the Phase 1/2 trial of Azedra[TM], will join the Molecular Insight team for a discussion of neuroendocrine tumors Neuroendocrine Tumors Definition Neuroendocrine tumor refers to the type of cell that a tumor grows from rather than where that tumor is located. and related clinical programs. Azedra is one of the company's lead targeted radiotherapeutic candidates for neuroendocrine neuroendocrine /neu·ro·en·do·crine/ (-en´do-krin) pertaining to neural and endocrine influence, and particularly to the interaction between the nervous and endocrine systems. neu·ro·en·do·crine adj. cancers. Dr. Coleman is a Professor of Radiology and Director of the Division of Nuclear Medicine at the Duke University School of Medicine and is board-certified in Nuclear Medicine and Internal Medicine. His research has been published in more than 400 scientific papers in several leading journals and he has published several textbooks related to nuclear medicine. Dr. Coleman is on the editorial board of several top medical journals, including The Journal of Nuclear Medicine, Radiology and Academic Radiology. Conference Call Details To access the live call on May 15, 2007 at 10:00 AM EDT, dial (800) 901-5218 or (617) 786-4511 (for international participants) at least 5 minutes prior to the start of the call. The participant pass code is 79217362. For one week following the call, an audio replay can be accessed by dialing (888) 286-8010 or (617) 801-6888 (international callers) and using the pass code 30930200. A live audio webcast of the call will also be available on the "Investor Relations Investor relations The process by which the corporation communicates with its investors. " section of the company's website, www.molecularinsight.com. An archived audio webcast will be available on the company's website after the event and will be archived for 30 days. About Molecular Insight Pharmaceuticals, Inc. Molecular Insight Pharmaceuticals (NASDAQ: MIPI) is a biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve healthcare for patients with life-threatening diseases. The company is focused on discovering, developing and commercializing innovative and targeted radiotherapeutics and molecular imaging pharmaceuticals with initial applications in the areas of oncology and cardiology cardiology Medical specialty dealing with heart diseases and disorders. It began with the 1749 publication by Jean Baptiste de Sénac of contemporary knowledge of the heart. Diagnostic methods improved in the 19th century, and in 1905 the electrocardiograph was invented. . Molecular Insight's lead targeted radiotherapeutic product candidates, Azedra and Onalta, are being developed for detection and treatment of cancer. The company's lead molecular imaging pharmaceutical product candidate, Zemiva, is being developed for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart. In addition, the company has a growing pipeline of product candidates resulting from application of its proprietary platform technologies to new and existing compounds. Molecular Insight Pharmaceuticals is based in Cambridge, Massachusetts This article is about the city of Cambridge in Massachusetts. For the English university town, see Cambridge, England. For other places, see Cambridge (disambiguation). Cambridge, Massachusetts is a city in the Greater Boston area of Massachusetts, United States. and its website address is: www.molecularinsight.com. Forward-Looking Statements Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about the development of Azedra[TM], Onalta [TM], Zemiva[TM] and our other product candidates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Molecular Insight to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. ; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Molecular Insight undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion